证券代码：600196 股票简称：复星医药 编号：临 2025-123 上海复星医药（集团）股份有限公司 关于控股子公司获美国 FDA 药品临床试验批准的公告 截至 2025 年 6 月，本集团（即本公司及控股子公司/单位）现阶段针对该新药 的累计研发投入约为人民币 1.82 亿元（未经审计，单药）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司 上海复宏汉霖生物技术股份有限公司及其控股子公司（以下合称"复宏汉霖"）获美 国 FDA（即美国食品药品监督管理局）批准开展注射用 HLX43（即靶向 PD-L1 抗体偶 联药物，以下简称"该新药"）用于治疗胸腺癌（TC）的 I 期临床试验。复宏汉霖 拟于条件具备后于澳大利亚、日本、美国等地开展该适应症的全球多中心临床研究。 二、该新药的研究情况 该新药为复宏汉霖将许可引进的新型 DNA 拓扑异构酶 I 抑制剂小分子毒素-肽链 连接子与复宏汉霖自主研发的靶向 PD-L1 的抗体进行偶联开发的靶向 PD- ...

Core Viewpoint - Fosun Pharma's subsidiary, Hanhui, has received FDA approval to conduct a Phase I clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate for the treatment of thymic carcinoma [1] Company Summary - Fosun Pharma announced on August 7 that its subsidiary, Hanhui, has been granted approval by the U.S. FDA to initiate a Phase I clinical trial for HLX43 [1] - The clinical trial will focus on thymic carcinoma and is planned to be conducted in multiple global centers, including Australia, Japan, and the United States, once conditions are met [1] Industry Summary - The approval of HLX43 for thymic carcinoma represents a significant advancement in the oncology sector, particularly in targeted therapies [1] - The global multi-center clinical research indicates a strategic approach to expanding the drug's market potential across different regions [1]

格隆汇8月7日丨复星医药(600196.SH)公布，控股子公司上海复宏汉霖生物技术股份有限公司及其控股 子公司获美国FDA（即美国食品药品监督管理局）批准开展注射用HLX43（即靶向PD-L1抗体偶联药 物，简称"该新药"）用于治疗胸腺癌（TC）的I期临床试验。复宏汉霖拟于条件具备后于澳大利亚、日 本、美国等地开展该适应症的全球多中心临床研究。该新药为复宏汉霖将许可引进的新型DNA拓扑异 构酶I抑制剂小分子毒素-肽链连接子与复宏汉霖自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD- L1的抗体偶联药物（ADC），拟用于晚期/转移性实体瘤的治疗。 ...

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Fuhong Hanlin, has received FDA approval to conduct a Phase I clinical trial for HLX43, a new drug aimed at treating thymic cancer [1] - Fuhong Hanlin plans to conduct global multi-center clinical research for this indication in Australia, Japan, and the United States once conditions are met [1] - The new drug is a targeted antibody-drug conjugate (ADC) developed by linking a novel DNA topoisomerase I inhibitor small molecule toxin-peptide chain conjugate with a self-developed PD-L1 targeted antibody, intended for the treatment of advanced/metastatic solid tumors [1] - As of June 2025, the total R&D investment for this new drug is approximately RMB 182 million [1]

企查查APP显示，近日，成都甲辰炘然科技合伙企业（有限合伙）成立，出资额790万元，经营范围包 含：企业管理咨询；货物进出口；技术进出口；信息技术咨询服务；医学研究和试验发展等。企查查股 权穿透显示，该合伙企业由复星医药（600196）旗下上海复星平耀投资管理有限公司、陈殿军共同持 股。 （原标题：复星医药等在成都成立科技合伙企业） ...

Group 1 - The stock price of XD Fosun Pharma (600196) closed at 26.84 yuan on August 4, 2025, down by 1.47%, with a turnover rate of 1.89% and a trading volume of 401,400 shares, resulting in a transaction amount of 1.064 billion yuan [1] - On August 4, the net outflow of main funds was 41.34 million yuan, accounting for 3.89% of the total transaction amount; the net outflow of speculative funds was 22.10 million yuan, accounting for 2.08%; while retail investors had a net inflow of 63.45 million yuan, accounting for 5.96% of the total transaction amount [2][5] - Fosun Pharma submitted a monthly report on securities changes to the Hong Kong Stock Exchange, covering statutory/registered capital changes, issued shares, and inventory shares as of July 31, 2025 [3][5] Group 2 - For H-shares, the statutory/registered share number remained at 551,940,500 shares, with issued shares totaling 540,971,500 shares and inventory shares at 10,969,000 shares, showing no changes for the month [3] - For A-shares, the statutory/registered share number was 2,118,488,825 shares, with issued shares totaling 2,098,582,573 shares and inventory shares at 19,906,252 shares, also showing no changes for the month [3] - The total statutory/registered capital at the end of the month was 2.670 billion yuan, with no applicable changes in stock options, warrants, convertible bonds, or other agreements [4]

Group I - The report details the changes in the registered capital of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. as of July 31, 2025, indicating no increase or decrease in the registered capital for the month [1]. - The total registered capital at the end of the month is RMB 2,670,429,325, with no changes reported from the previous month [1]. - The number of issued shares (excluding treasury shares) remains unchanged at 540,971,500 for the security code 02196 and 2,098,582,573 for the security code 600196 [1]. Group II - The report confirms that all securities issuance or treasury share transactions have been authorized by the board of directors and comply with applicable listing rules and regulations [2]. - It states that all necessary conditions for listing have been fulfilled, and all required documents have been filed with the relevant authorities [2]. - The report also confirms that all ownership documents related to the issuance, sale, or transfer of shares have been prepared and sent as required [2].

截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 | RMB | | 551,940,500 | | 增加 / 減少 (-) | | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 | RMB ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 | RMB | | 551,940,500 | | 增加 / 減少 (-) | | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 | RMB ...

港股医药股震荡走低，华润医疗跌超13%，石药集团、复星医药、微创医疗、药明康德、药明生物等跟 跌。 ...